Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Edgewise Therapeutics

< Previous 1 2 Next >
Edgewise Therapeutics Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker)
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics to Present at the Goldman Sachs Global Healthcare Conference
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics to Present at Upcoming Investor Conferences
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of Duchenne Muscular Dystrophy (DMD)
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics to Present at the Cowen 43rd Annual Health Care Conference on March 8, 2023
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics Announces Upcoming Presentation at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of Cardiology
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics to Present at the SVB Securities Global Biopharma Conference on February 14, 2023
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics to Showcase Novel Cardiac Program at Virtual Investor Event on Tuesday, January 3, 2023
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics to Present at Upcoming Investor Conferences
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics Reports Third Quarter 2022 Financial Results
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics Announces Positive 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 27th International Hybrid Annual Congress of the World Muscle Society
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics Announces Proposed Offering of Common Stock
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on August 9
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
From Edgewise Therapeutics
Via Business Wire
Tickers EWTX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.